Stunning Response with Low-Dose Enzalutamide after Abiraterone Acetate Failure in a Patient Diagnosed with Metastatic Castration-Resistant Prostate Cancer: A Case Report

Luigi Rossi; Giuseppe Cimino; Elisa Gozzi; Marsela Sinjari; Martina Brandi; Serena Ceddia; Antonella Cosimati; Lucrezia Raimondi; Antonella Fontana; Luca Filippi; Oreste Bagni; Gian Paolo Spinelli

doi:10.1159/000514979

Case Reports in Oncology (Mar 2021)

Stunning Response with Low-Dose Enzalutamide after Abiraterone Acetate Failure in a Patient Diagnosed with Metastatic Castration-Resistant Prostate Cancer: A Case Report

Luigi Rossi,
Giuseppe Cimino,
Elisa Gozzi,
Marsela Sinjari,
Martina Brandi,
Serena Ceddia,
Antonella Cosimati,
Lucrezia Raimondi,
Antonella Fontana,
Luca Filippi,
Oreste Bagni,
Gian Paolo Spinelli

Affiliations

Luigi Rossi: UOC of Oncology – ASL Latina – Distretto 1, University of Rome “Sapienza”, Aprilia, Italy
Giuseppe Cimino: Department of Cellular Biotechnology and Hematology, University of Rome “Sapienza”, Rome, Italy
Elisa Gozzi: UOC of Oncology – ASL Latina – Distretto 1, University of Rome “Sapienza”, Aprilia, Italy
Marsela Sinjari: UOC of Oncology – ASL Latina – Distretto 1, University of Rome “Sapienza”, Aprilia, Italy
Martina Brandi: UOC of Oncology – ASL Latina – Distretto 1, University of Rome “Sapienza”, Aprilia, Italy
Serena Ceddia: UOC of Oncology – ASL Latina – Distretto 1, University of Rome “Sapienza”, Aprilia, Italy
Antonella Cosimati: UOC of Oncology – ASL Latina – Distretto 1, University of Rome “Sapienza”, Aprilia, Italy
Lucrezia Raimondi: UOC of Oncology – ASL Latina – Distretto 1, University of Rome “Sapienza”, Aprilia, Italy
Antonella Fontana: Department of Radiotherapy, Santa Maria Goretti Hospital, Latina, Italy
Luca Filippi: Department of Nuclear Medicine, Santa Maria Goretti Hospital, Latina, Italy
Oreste Bagni: Department of Nuclear Medicine, Santa Maria Goretti Hospital, Latina, Italy
Gian Paolo Spinelli: UOC of Oncology – ASL Latina – Distretto 1, University of Rome “Sapienza”, Aprilia, Italy

DOI: https://doi.org/10.1159/000514979
Journal volume & issue: Vol. 14, no. 1
pp. 634 – 640

Abstract

Read online

We report a case of an elderly patient with metastatic castration-resistant prostate cancer, initially treated with abiraterone acetate (1,000 mg/day) combined with LH-RH antagonist, prednisone (10 mg/day), and zoledronic acid to manage bone metastases. In consideration of his poor performance status, radiological and biochemical progression of the disease, we decided to switch abiraterone to enzalutamide (160 mg/day). Due to adverse events, we reduced enzalutamide to a dose of 80 mg/day. Currently, the disease is under control despite the use of a low dose of enzalutamide.

Published in Case Reports in Oncology

ISSN: 1662-6575 (Online)
Publisher: Karger Publishers
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: http://www.karger.com/cro

About the journal

Abstract

Keywords